Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
1.38B
Market cap1.38B
Price-Earnings ratio
-8.52
Price-Earnings ratio-8.52
Dividend yield
Dividend yield
Average volume
6.43M
Average volume6.43M
High today
$19.17
High today$19.17
Low today
$11.89
Low today$11.89
Open price
$16.98
Open price$16.98
Volume
78.44M
Volume78.44M
52 Week high
$150.48
52 Week high$150.48
52 Week low
$11.89
52 Week low$11.89

SRPT News

Sherwood News 6h
Sarepta dives on reports that FDA will ask it to stop selling gene treatment

The Food and Drug Administration will request Sarepta Therapeutics to stop all shipments of its most lucrative drug after it disclosed last month that a second...

Sarepta dives on reports that FDA will ask it to stop selling gene treatment
Seeking Alpha 7h
Sarepta plunges as FDA is reportedly evaluating if gene therapy should remain on market

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped to a new 52-week low on Friday, triggering a trading halt after Bloomberg News reported that the FDA is review...

Sarepta plunges as FDA is reportedly evaluating if gene therapy should remain on market
CNBC 7h
Sarepta shares plunge 30% as future of its gene therapy appears at risk

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 202...

Sarepta shares plunge 30% as future of its gene therapy appears at risk

Analyst ratings

48%

of 27 ratings
Buy
44.4%
Hold
48.1%
Sell
7.4%

More SRPT News

TipRanks 9h
Sarepta downgraded to Hold from Buy at Needham

Needham analyst Gil Blum downgraded Sarepta (SRPT) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Benzinga 9h
Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding...

Sarepta's Setback Deepens With Another Gene Therapy Fatality
TipRanks 10h
Sarepta CEO says didn’t disclose patient death on Weds. call, ‘wasn’t salient’

The company, on an update conference call, says it didn’t disclose the limb girdle patient death on the Wednesday update call as it “wasn’t salient to our discu...

Benzinga 13h
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics SRPT plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marki...

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Benzinga 1d
Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics, Inc. SRPT stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevid...

Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Benzinga 2d
Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc SRPT shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measu...

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.